Table 1.
Characteristics of the 902 patients who received nivolumab enrolled in the IFCT 1502-CLINIVO study
| Squamous (n = 317) | Non-squamous (n = 585) | Total (N = 902) | |||
|---|---|---|---|---|---|
| Sex | F | n (%) | 58 (18.3) | 214 (36.6) | 272 (30.2) |
| Age (years) | Median | 66 | 63 | 64 | |
| Range | (36.4-86.6) | (34.1-88.2) | (34.1-88.2) | ||
| Smoking | Never smoker | n (%) | 18 (5.7) | 88 (15.1) | 795 (88.2) |
| Smoker | n (%) | 299 (94.3) | 496 (84.9) | 106 (11.8) | |
| Number of pack-years | Median | 40 | 35 | 40 | |
| Range | (1-130) | (0.3-132) | (0.3-132) | ||
| Number of prior lines | 1 | n (%) | 80 (25.2) | 163 (27.9) | 243 (26.9) |
| 2 | n (%) | 115 (36.3) | 170 (29.1) | 285 (31.6) | |
| 3 | n (%) | 64 (20.2) | 113 (19.3) | 177 (19.6) | |
| 4 | n (%) | 44 (13.9) | 71 (12.1) | 115 (12.7) | |
| >4 | n (%) | 14 (4.4) | 68 (11.6) | 82 (9.1) | |
| Brain metastasis (at initiation of nivolumab) | No | n (%) | 277 (87.4) | 428 (73.2) | 705 (78.2) |
| Yes | n (%) | 40 (12.6) | 157 (26.8) | 197 (21.8) | |
| PD-L1 (IHC) | Negative | n (%) | 18 (85.7) | 32 (57.1) | 50 (64.9) |
| Positive | n (%) | 3 (14.3) | 21 (37.5) | 24 (31.2) | |
| Performance status (initiation of nivolumab) | 0 | n (%) | 63 (20) | 134 (23.2) | 197 (22.1) |
| 1 | n (%) | 195 (61.9) | 331 (57.3) | 526 (58.9) | |
| 2 | n (%) | 49 (15.6) | 99 (17.1) | 148 (16.6) | |
| 3 | n (%) | 6 (1.9) | 13 (2.2) | 19 (2.1) | |
| 4 | n (%) | 2 (0.6) | 1 (0.2) | 3 (0.3) | |
| Missing | n | 2 | 7 | 9 | |
IFCT, French Cooperative Thoracic Intergroup; IHC, immunohistochemistry; PD-L1, programmed death-ligand 1.